Eli Lilly is buying a rare blood cancer biotech for up to $1.5 billion

Summary
The deal covers Calytrix's preclinical antibody for essential thrombocythemia and myelofibrosis, with milestone payments included
Description from Quartz.
Who is covering this
-
Eli Lilly is buying a rare blood cancer biotech for up to $1.5 billion
The deal covers Calytrix's preclinical antibody for essential thrombocythemia and myelofibrosis, with milestone payments included




Comments
Comments need JavaScript.